Literature DB >> 10564580

Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma.

L Wang1, J Darling, J S Zhang, W Liu, J Qian, D Bostwick, L Hartmann, R Jenkins, W Bardenhauer, J Schutte, B Opalka, D I Smith.   

Abstract

Consistent deletion of DNA sequences in chromosomal band 3p21 observed in a variety of human tumors suggests the presence of one or more tumor suppressor genes within this region. Previously, we reported on the construction of two distinct cosmid contigs and our identification of several new genes within 3p21.1. In our search for tumor suppressor genes from this region, we have cloned a gene that we have called DRR 1 (downregulated in renal cell carcinoma). The gene was first mapped to 3p21.1 by fluorescence in situ hybridization analysis. Further analysis of yeast artificial chromosome clones in 3p14.2-p21.1 refined its localization. DRR 1 spans about 10 Kb of genomic DNA with a 3.5-Kb mature transcript. The putative protein encoded by this gene is 144 amino acids and includes a nuclear localization signal and a coiled domain. The gene showed loss of expression in eight of eight renal cell carcinoma cell lines, one of seven ovarian cancer cell lines, one of one cervical cancer cell line, one of one gastric cancer cell line, and one of one non-small-cell lung cancer cell line. Southern blot analysis did not show any altered bands, indicating that gross structural changes or deletions did not cause the loss of expression. This gene was also found to have reduced expression in 23 of 34 paired primary renal cell carcinomas. Mutational analysis detected three polymorphic sites within the gene, but no point mutations were identified in the 34 primary tumors. However, we did detect base substitutions in 4 of 12 cell lines that had undetectable expression of the gene. We also transfected the gene into DRR 1-negative cell lines and observed clear growth retardation. Our results suggest that loss of expression of the DRR 1 gene may play an important role in the development of renal cell carcinoma and possibly other tumors. Genes Chromosomes Cancer 27:1-10, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10564580     DOI: 10.1002/(sici)1098-2264(200001)27:1<1::aid-gcc1>3.0.co;2-6

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Association of Abl interactor 2, ABI2, with platelet/lymphocyte ratio in patients with renal cell carcinoma: A pilot study.

Authors:  Sercan Ergun; Sezgin Gunes; Recep Buyukalpelli; Oguz Aydin
Journal:  Int J Exp Pathol       Date:  2020-06-04       Impact factor: 1.925

2.  Epigenomic alterations in localized and advanced prostate cancer.

Authors:  Pei-Chun Lin; Eugenia G Giannopoulou; Kyung Park; Juan Miguel Mosquera; Andrea Sboner; Ashutosh K Tewari; Levi A Garraway; Himisha Beltran; Mark A Rubin; Olivier Elemento
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

3.  A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-κB degradation and cell growth suppression in neuroblastoma.

Authors:  P Mu; T Akashi; F Lu; S Kishida; K Kadomatsu
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

4.  Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor.

Authors:  Raoul Frijters; Wilco Fleuren; Erik J M Toonen; Jan P Tuckermann; Holger M Reichardt; Hans van der Maaden; Andrea van Elsas; Marie-Jose van Lierop; Wim Dokter; Jacob de Vlieg; Wynand Alkema
Journal:  BMC Genomics       Date:  2010-06-05       Impact factor: 3.969

5.  On the statistical assessment of classifiers using DNA microarray data.

Authors:  N Ancona; R Maglietta; A Piepoli; A D'Addabbo; R Cotugno; M Savino; S Liuni; M Carella; G Pesole; F Perri
Journal:  BMC Bioinformatics       Date:  2006-08-19       Impact factor: 3.169

6.  Comprehensive exploration of novel chimeric transcripts in clear cell renal cell carcinomas using whole transcriptome analysis.

Authors:  Masahiro Gotoh; Hitoshi Ichikawa; Eri Arai; Suenori Chiku; Hiromi Sakamoto; Hiroyuki Fujimoto; Masaki Hiramoto; Takao Nammo; Kazuki Yasuda; Teruhiko Yoshida; Yae Kanai
Journal:  Genes Chromosomes Cancer       Date:  2014-09-18       Impact factor: 5.006

7.  Combined deletion and DNA methylation result in silencing of FAM107A gene in laryngeal tumors.

Authors:  Katarzyna Kiwerska; Marcin Szaumkessel; Julia Paczkowska; Magdalena Bodnar; Ewa Byzia; Ewelina Kowal; Magdalena Kostrzewska-Poczekaj; Joanna Janiszewska; Kinga Bednarek; Małgorzata Jarmuż-Szymczak; Ewelina Kalinowicz; Małgorzata Wierzbicka; Reidar Grenman; Krzysztof Szyfter; Andrzej Marszałek; Maciej Giefing
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

8.  Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells.

Authors:  Amy E Arnold; Elise Malek-Adamian; Phuong U Le; Anika Meng; Saúl Martínez-Montero; Kevin Petrecca; Masad J Damha; Molly S Shoichet
Journal:  Mol Ther Nucleic Acids       Date:  2018-04-19       Impact factor: 8.886

9.  HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth.

Authors:  Kurosh Ameri; Arman Jahangiri; Anthony M Rajah; Kathryn V Tormos; Ravi Nagarajan; Melike Pekmezci; Vien Nguyen; Matthew L Wheeler; Michael P Murphy; Timothy A Sanders; Stefanie S Jeffrey; Yerem Yeghiazarians; Paolo F Rinaudo; Joseph F Costello; Manish K Aghi; Emin Maltepe
Journal:  Cell Rep       Date:  2015-02-13       Impact factor: 9.423

10.  Family with sequence similarity 107: A family of stress responsive small proteins with diverse functions in cancer and the nervous system (Review).

Authors:  Hideo Nakajima; Keita Koizumi
Journal:  Biomed Rep       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.